1828 results about "Pyran" patented technology

Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other non-limiting embodiments relate to photochromic-dichroic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. For example, one non-limiting embodiment provides a thermally reversible, photochromic compound adapted to have at least a first state and a second state, wherein the thermally reversible, photochromic compound has an average absorption ratio greater than 2.3 in at least one state as determined according to CELL METHOD. Another non-limiting embodiment provides a photochromic compound comprising: (a) at least one photochromic group chosen from a pyran, an oxazine, and a fulgide; and (b) at least one lengthening agent L attached to the at least one photochromic group and represented by the formula —[S₁]_c-[Q₁-[S₂]_d]_d′-[Q₂-[S₃]_e]_e′-[Q₃-[S₄]_f]_f′—S₅—P, which is described herein.

Photochromic diaryl-2H-naphthopyran structures, which dye photochromically well at room temperature, lighten up quickly when incorporated into ophthalmic lenses, possess longevity, and due to their spacial structures, have a reduced tendency of the molecules to migrate in plastics.

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001"/>(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup

A photochromic naphthopyran displays good color distribution when the naphthopyran has a central nucleus of the formula:

• • wherein F is a 5-member, 6-member, or 7-member heterocyclic ring group having only one heteroatom, the heteroatom selected from the group consisting of oxygen, sulfur, and nitrogen, the 2,3 or 3,2 positions of the heterocyclic ring fused to the g, h, or i side;
  • R₁ and R₂ are the atoms or groups providing photochromic properties to the naphthopyran.

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Described herein are compounds generally comprising an indeno[2′,3′:3,4]naptho[1,2-b]pyran structure. Such compounds may be useful for their photochromic properties, and be used in certain photochromic compositions. Such compositions may further comprise other photochromic compositions and/or materials. Additionally, such compounds and/or compositions may be suitable for preparing certain photochromic articles. Also described herein are methods for preparing certain photochromic compounds, compositions, and articles.

The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.

Various non-limiting embodiments of the present invention relate to photochromic materials having a metallocenyl group. More particularly, various non-limiting embodiments disclosed herein provide photochromic materials including an indeno-fused naphthopyran, such as an indeno[2′,3′:3,4]naphtho[1,2-b]pyran, and a metallocenyl group bonded to at least one available position on the indeno-fused naphthopyran. Other non-limiting embodiments disclosed herein provide photochromic composition and photochromic articles, such as but not limited to ophthalmic lens, which include the disclosed photochromic materials and method of making the same.

The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.

The invention provides a phenanthrene and imidazole-coumarin double-fluorescent group ratio fluorescent molecular probe for iron ion detection and synthesis and use methods thereof, relates to fluorescent molecular probes and synthesis and application thereof and aims to solve the problem that an existing Fe<3+> fluorescent probe is prone to being interfered by pH, concentration and other metal ions. The fluorescent molecular probe is 4-methyl-7-hydroxide radical-8-[2-(1- phenyl group-1H-phenanthrene and [9, 10-d] imidazole-2-)benzene ammonia methylene]-2H-pyran-2-ketone. The phenanthrene and imidazole-coumarin double-fluorescent group ratio fluorescent molecular probe is formed by conducting condensation on 1-N-phenyl group-2-(2-aminophenyl)-1H-phenanthrene and [9, 10-d] imidazole and 4-methyl-7-hydroxide radical-8- formyl group coumarin, and the yield is 75-85%. The fluorescent molecular probe is dissolved in mixed liquid of N, N- dimethylformamide and an HEPES buffering solution, existence of iron ions is judged through the absorbance value or fluorescence intensity change before and after adding of test samples, and the fluorescent molecular probe can be used for detection of Fe<3+> pollution in water.

The present invention is directed to novel substituted aminotetrahydropyrans of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Provided are O²-glycosylated 1-substituted diazen-1-ium-1,2-diolates (O²-glycosylated diazeniumdiolates) having the formula:

in which R is a saccharide, which is attached to the O² of the compound by the anomeric carbon of a pyranose ring or a furanose ring.

A liquid crystal compound selected from a group of compounds represented by formula (a):

wherein Ra and Rb are each independently alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons, alkoxyalkyl having 2 to 9 carbons, alkenyl having 2 to 10 carbons, alkenyloxy having 2 to 9 carbons, fluoroalkyl having 1 to 10 carbons or fluoroalkoxy having 1 to 9 carbons; ring A¹, ring A² and ring A³ are each independently trans-1,4-cyclohexylene, trans-1,3-dioxane-2,5-diyl, trans-tetrahydropyran-2,5-diyl, 1,4-phenylene, 2-fluoro-1,4-phenylene, 2,3-difluoro-1,4-phenylene, 2,5-difluoro-1,4-phenylene, 2,6-difluoro-1,4-phenylene, pyridine-2,5-diyl, 6-fluoropyridine-2,5-diyl or pyridazine-2,5-diyl; Z¹, Z² and Z³ are each independently a single bond, —(CH₂)₂—, —CH═CH—, —C≡C—, —CH₂O, —OCH₂—, —COO—, —OCO—, —OCF₂—, —CF₂O—, —CH₂CH₂OCF₂— or —CF₂OCH₂CH₂—; l, m and n are each independently 0, 1 or 2, provided that l+m+n is 0, 1, 2 or 3; one of X¹ and X² is fluorine, and the other is chlorine; Q is

and atoms comprising the compound each may be an isotope thereof.

The invention relates to a high luminance, high efficiency indole 3,2-b carbazole derivatives organic electroluminescenct material, belonging to the organic electroluminescent material technical field. The general structural formula of the indole 3,2-b carbazole derivatives organic electroluminescent compound is in the picture; in which, R3, R7 is alkyl or the substitute aryl, R1, R2 or R4-R6, R8 is hydrogen atom, benzene, naphthaline, anthracene, fluorine, carbazole, triarylated amine, thiophene, pyridine, pyran, quinoline, pyrrole, furan or imidazole. The compound of the invention has high fluorescence in both solution and solid film and has high film forming ability, thermal stability and photostability.

Disclosed is an optical film having a hard coat layer on a cellulose ester film, which contains an ester compound composed of a furanose structure or a pyranose structures and a sum of a number of the furanose structures or the pyranose structure is 1 to 12, provided that a part of hydroxy groups of the furanose structure or the pyranose structure has been esterified and a part of hydroxy groups of the furanose structure or the pyranose structure remains.